pubmed-article:12892767 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0441471 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0009566 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0253563 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0288672 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
pubmed-article:12892767 | lifeskim:mentions | umls-concept:C0522523 | lld:lifeskim |
pubmed-article:12892767 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:12892767 | pubmed:dateCreated | 2003-8-1 | lld:pubmed |
pubmed-article:12892767 | pubmed:abstractText | Glycoprotein IIb/IIIa antagonists reduce peri-angioplasty ischemic complications and improve in-hospital outcome in patients undergoing percutaneous coronary interventions (PCI). Prior studies have demonstrated favorable results with both eptifibatide and abciximab. The purpose of this study was to assess whether there are any differences in rates of acute procedural complications and in-hospital events with the use of these two agents. | lld:pubmed |
pubmed-article:12892767 | pubmed:language | eng | lld:pubmed |
pubmed-article:12892767 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12892767 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12892767 | pubmed:issn | 1522-1865 | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:GrubergLuisL | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:WaksmanRonR | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:KentKenneth... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:AjaniAndrew... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:PinnowEllenE | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:CheneauEdouar... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:CanosDaniel... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:SharmaArvind... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:CastagnaMarco... | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:SatlerLowellL | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:LewRobertR | lld:pubmed |
pubmed-article:12892767 | pubmed:author | pubmed-author:PichardAugust... | lld:pubmed |
pubmed-article:12892767 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12892767 | pubmed:volume | 4 | lld:pubmed |
pubmed-article:12892767 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12892767 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12892767 | pubmed:pagination | 12-7 | lld:pubmed |
pubmed-article:12892767 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:meshHeading | pubmed-meshheading:12892767... | lld:pubmed |
pubmed-article:12892767 | pubmed:articleTitle | Acute procedural complications and in-hospital events after percutaneous coronary interventions: eptifibatide versus abciximab. | lld:pubmed |
pubmed-article:12892767 | pubmed:affiliation | Washington Hospital Center, 110 Irving Street, NW, Suite 4B-1, Washington, DC 20010, USA. | lld:pubmed |
pubmed-article:12892767 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12892767 | pubmed:publicationType | Comparative Study | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12892767 | lld:pubmed |